NTRA logo

Natera

NTRA · What the business does, what can go wrong, and how options sellers approach it

What it does

Natera is a genetic testing company. It develops blood-based tests that analyze small fragments of DNA circulating in the body, known as cell-free DNA. Its main product areas are women's health, oncology and organ health.

In women's health, Panorama is a prenatal screening test, and Horizon is a carrier screening test that shows whether parents carry genes for certain inherited conditions. In oncology, Signatera looks for traces of tumor DNA in people previously treated for cancer to help detect residual disease or recurrence. In organ health, Prospera helps assess possible rejection of a transplanted organ.

How it makes money

Natera earns revenue each time a test is performed. Payment typically comes from insurers, government programs, hospitals, clinics or patients. Whether a test is covered, and at what rate, has a large effect on how much revenue each test brings in. The company also earns smaller amounts from research and biopharma partners who use its technology.

Why investors own it

  • Growth in testing: Genetic and blood-based testing has been widening into more areas of medicine.
  • Repeat use: Cancer monitoring can involve testing at several points over time, which can support recurring volume.
  • Technology and data: A large body of clinical evidence can help win physician adoption and insurance coverage.
  • Operating leverage: If volume grows faster than costs, margins can improve.

What can go wrong

  • Insurers may deny coverage or pay less than expected.
  • Competitors in prenatal and cancer testing can pressure prices and market share.
  • Patent and legal disputes, including challenges over billing or marketing, can be costly.
  • Regulation of lab-developed tests could change.
  • The company has historically spent heavily to grow, so profitability and cash needs matter.
  • Clinical evidence may fall short of what doctors and payers want to see.

What to watch

  • Test volumes by product line
  • Average revenue per test
  • Payer coverage decisions and reimbursement updates
  • Gross margin
  • Operating cash flow and path to sustained profitability
  • New clinical study results for Signatera
  • Regulatory developments for lab-developed tests

Options income angle

Options on NTRA are generally listed across a range of strikes and expirations, and liquidity is typically best in near-term, near-the-money contracts, with wider bid-ask spreads further out. Implied volatility tends to rise ahead of quarterly earnings, clinical data releases, coverage decisions and legal rulings. One caution for premium sellers: a healthcare stock like this can gap sharply on a single announcement, so a short option position can lose far more than the premium collected, especially if the stock moves quickly past the strike.

Follow NTRA in Kortex

The Kortex app shows NTRA's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.